[go: up one dir, main page]

UY35209A - Compuestos tricíclicos - Google Patents

Compuestos tricíclicos

Info

Publication number
UY35209A
UY35209A UY0001035209A UY35209A UY35209A UY 35209 A UY35209 A UY 35209A UY 0001035209 A UY0001035209 A UY 0001035209A UY 35209 A UY35209 A UY 35209A UY 35209 A UY35209 A UY 35209A
Authority
UY
Uruguay
Prior art keywords
tricyclic compounds
present
provides
compound
formula
Prior art date
Application number
UY0001035209A
Other languages
English (en)
Inventor
Mckenna Jeffrey
Graham Charles Bloomfield
Ahmed Mahbub
Gueritz Louisa
Mckenna Joseph
Mutton Simon
Parmar Rakesh
Shepherd Jon
Wright Paul
Alexander Ashall Kelly
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY35209A publication Critical patent/UY35209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
UY0001035209A 2012-12-19 2013-12-19 Compuestos tricíclicos UY35209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739337P 2012-12-19 2012-12-19
US201361906154P 2013-11-19 2013-11-19

Publications (1)

Publication Number Publication Date
UY35209A true UY35209A (es) 2014-07-31

Family

ID=50030371

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035209A UY35209A (es) 2012-12-19 2013-12-19 Compuestos tricíclicos

Country Status (15)

Country Link
US (1) US9303035B2 (es)
EP (1) EP2935277B1 (es)
JP (1) JP6284545B2 (es)
KR (1) KR20150095925A (es)
CN (1) CN105008370B (es)
AR (1) AR094123A1 (es)
AU (1) AU2013365827A1 (es)
BR (1) BR112015014433A2 (es)
CA (1) CA2895656A1 (es)
EA (1) EA201591175A1 (es)
ES (1) ES2650372T3 (es)
MX (1) MX2015007940A (es)
TW (1) TW201429976A (es)
UY (1) UY35209A (es)
WO (1) WO2014097147A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
US9359381B2 (en) 2012-12-19 2016-06-07 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
NZ743725A (en) * 2015-12-24 2024-11-29 Univ California Cftr regulators and methods of use thereof
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California MEDICINAL COMPOSITIONS FOR THE EYE
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
US20240252655A1 (en) 2021-04-29 2024-08-01 Novartis Ag Deubiquitinase-targeting chimeras and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224974B (es) * 1991-07-02 1994-06-11 Hoffmann La Roche
CA2382528A1 (en) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2464354B1 (en) * 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9062073B2 (en) * 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
US9359381B2 (en) 2012-12-19 2016-06-07 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel

Also Published As

Publication number Publication date
AU2013365827A1 (en) 2015-07-09
US20140171412A1 (en) 2014-06-19
ES2650372T3 (es) 2018-01-18
JP2016507498A (ja) 2016-03-10
MX2015007940A (es) 2016-03-11
US9303035B2 (en) 2016-04-05
EP2935277B1 (en) 2017-08-30
BR112015014433A2 (pt) 2017-07-11
JP6284545B2 (ja) 2018-02-28
CA2895656A1 (en) 2014-06-26
TW201429976A (zh) 2014-08-01
EP2935277A1 (en) 2015-10-28
AR094123A1 (es) 2015-07-08
WO2014097147A1 (en) 2014-06-26
CN105008370A (zh) 2015-10-28
KR20150095925A (ko) 2015-08-21
EA201591175A1 (ru) 2015-11-30
CN105008370B (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY35209A (es) Compuestos tricíclicos
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
CU20130094A7 (es) Moduladores de la vía del complemento
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
MX360495B (es) Derivados deuterados de ruxolitinib.
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
UY35211A (es) Compuestos tricíclicos
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
UY36124A (es) Derivados de carboxamida
UY33348A (es) Compuestos de furopiridina y usos de los mismos
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
UY33857A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos.
CU20160170A7 (es) Derivados de carboxamida
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CO7141426A2 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210715